Format

Send to

Choose Destination
Bioconjug Chem. 2018 Mar 21;29(3):587-603. doi: 10.1021/acs.bioconjchem.7b00808. Epub 2018 Feb 16.

Toll-like Receptor Agonist Conjugation: A Chemical Perspective.

Author information

1
Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences , Radboud University Medical Center , 6525 GA Nijmegen , The Netherlands.
2
Department of Chemistry , University of California, Irvine , Irvine , California 92697 , United States.
3
Institute for Molecular Engineering , University of Chicago , Chicago , Illinois 60637 , United States.

Abstract

Toll-like receptors (TLRs) are vital elements of the mammalian immune system that function by recognizing pathogen-associated molecular patterns (PAMPs), bridging innate and adaptive immunity. They have become a prominent therapeutic target for the treatment of infectious diseases, cancer, and allergies, with many TLR agonists currently in clinical trials or approved as immunostimulants. Numerous studies have shown that conjugation of TLR agonists to other molecules can beneficially influence their potency, toxicity, pharmacokinetics, or function. The functional properties of TLR agonist conjugates, however, are highly dependent on the ligation strategy employed. Here, we review the chemical structural requirements for effective functional TLR agonist conjugation. In addition, we provide similar analysis for those that have yet to be conjugated. Moreover, we discuss applications of covalent TLR agonist conjugation and their implications for clinical use.

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center